Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida. more
Time Frame | NEO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.34% | -3.72% | -0.05% |
1-Month Return | 19.72% | -1.85% | 2.75% |
3-Month Return | 10.04% | -11.4% | 7.4% |
6-Month Return | 37.18% | -4.41% | 10.47% |
1-Year Return | -3.49% | 4.13% | 27.57% |
3-Year Return | -43.1% | 0.3% | 29.56% |
5-Year Return | -32.92% | 36.62% | 89.3% |
10-Year Return | 335.11% | 106.81% | 206.09% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 408.83M | 444.45M | 484.33M | 509.73M | 591.64M | [{"date":"2019-12-31","value":69.1,"profit":true},{"date":"2020-12-31","value":75.12,"profit":true},{"date":"2021-12-31","value":81.86,"profit":true},{"date":"2022-12-31","value":86.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 211.99M | 258.56M | 297.27M | 321.83M | 347.04M | [{"date":"2019-12-31","value":61.09,"profit":true},{"date":"2020-12-31","value":74.5,"profit":true},{"date":"2021-12-31","value":85.66,"profit":true},{"date":"2022-12-31","value":92.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 196.84M | 185.89M | 187.06M | 187.90M | 244.60M | [{"date":"2019-12-31","value":80.47,"profit":true},{"date":"2020-12-31","value":76,"profit":true},{"date":"2021-12-31","value":76.47,"profit":true},{"date":"2022-12-31","value":76.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 48.15% | 41.83% | 38.62% | 36.86% | 41.34% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":86.87,"profit":true},{"date":"2021-12-31","value":80.22,"profit":true},{"date":"2022-12-31","value":76.56,"profit":true},{"date":"2023-12-31","value":85.87,"profit":true}] |
Operating Expenses | 183.83M | 199.88M | 305.81M | 341.00M | 341.25M | [{"date":"2019-12-31","value":53.87,"profit":true},{"date":"2020-12-31","value":58.57,"profit":true},{"date":"2021-12-31","value":89.62,"profit":true},{"date":"2022-12-31","value":99.93,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 8.38M | (2.13M) | (9.99M) | (153.11M) | (107.74M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-25.44,"profit":false},{"date":"2021-12-31","value":-119.31,"profit":false},{"date":"2022-12-31","value":-1827.93,"profit":false},{"date":"2023-12-31","value":-1286.25,"profit":false}] |
Total Non-Operating Income/Expense | (8.44M) | (7.08M) | 98.60M | (3.23M) | 20.63M | [{"date":"2019-12-31","value":-8.56,"profit":false},{"date":"2020-12-31","value":-7.18,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-3.27,"profit":false},{"date":"2023-12-31","value":20.93,"profit":true}] |
Pre-Tax Income | 3.65M | (14.06M) | (15.07M) | (159.34M) | (97.10M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-385.62,"profit":false},{"date":"2021-12-31","value":-413.58,"profit":false},{"date":"2022-12-31","value":-4371.52,"profit":false},{"date":"2023-12-31","value":-2663.84,"profit":false}] |
Income Taxes | (4.36M) | (18.23M) | (6.73M) | (15.09M) | (9.13M) | [{"date":"2019-12-31","value":-436100000,"profit":false},{"date":"2020-12-31","value":-1822800000,"profit":false},{"date":"2021-12-31","value":-672800000,"profit":false},{"date":"2022-12-31","value":-1509200000,"profit":false},{"date":"2023-12-31","value":-912900000,"profit":false}] |
Income After Taxes | 8.01M | 4.17M | (8.35M) | (144.25M) | (87.97M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":52.11,"profit":true},{"date":"2021-12-31","value":-104.26,"profit":false},{"date":"2022-12-31","value":-1801.77,"profit":false},{"date":"2023-12-31","value":-1098.78,"profit":false}] |
Income From Continuous Operations | 8.01M | 4.17M | (8.35M) | (144.25M) | (87.97M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":52.11,"profit":true},{"date":"2021-12-31","value":-104.26,"profit":false},{"date":"2022-12-31","value":-1801.77,"profit":false},{"date":"2023-12-31","value":-1098.78,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 8.01M | 4.17M | (8.35M) | (144.25M) | (87.97M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":52.11,"profit":true},{"date":"2021-12-31","value":-104.26,"profit":false},{"date":"2022-12-31","value":-1801.77,"profit":false},{"date":"2023-12-31","value":-1098.78,"profit":false}] |
EPS (Diluted) | 0.31 | 0.14 | (0.27) | (0.56) | (0.26) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":45.16,"profit":true},{"date":"2021-12-31","value":-87.1,"profit":false},{"date":"2022-12-31","value":-180.65,"profit":false},{"date":"2023-12-31","value":-83,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
NEO | |
---|---|
Cash Ratio | 1.31 |
Current Ratio | 1.99 |
Quick Ratio | 1.91 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NEO | |
---|---|
ROA (LTM) | -2.76% |
ROE (LTM) | -8.38% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NEO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.45 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.55 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NEO | |
---|---|
Trailing PE | NM |
Forward PE | 222.22 |
P/S (TTM) | 3.58 |
P/B | 2.51 |
Price/FCF | NM |
EV/R | 3.87 |
EV/Ebitda | NM |
PEG | 3.02 |
NeoGenomics Inc (NEO) share price today is $17.97
Yes, Indians can buy shares of NeoGenomics Inc (NEO) on Vested. To buy NeoGenomics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NEO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of NeoGenomics Inc (NEO) via the Vested app. You can start investing in NeoGenomics Inc (NEO) with a minimum investment of $1.
You can invest in shares of NeoGenomics Inc (NEO) via Vested in three simple steps:
The 52-week high price of NeoGenomics Inc (NEO) is $21.22. The 52-week low price of NeoGenomics Inc (NEO) is $12.77.
The price-to-earnings (P/E) ratio of NeoGenomics Inc (NEO) is
The price-to-book (P/B) ratio of NeoGenomics Inc (NEO) is 2.51
The dividend yield of NeoGenomics Inc (NEO) is 0.00%
The market capitalization of NeoGenomics Inc (NEO) is $2.31B
The stock symbol (or ticker) of NeoGenomics Inc is NEO